They do have other potential blockbusters in the pipeline such as Garadacimab (CSL312), a novel, fully-human monoclonal antibody that inhibits activated factor XII (FXIIa), for the prevention of hereditary angioedema attacks. Phase III trials complete. Forecast to add $50 to share price
They do have other potential blockbusters in the pipeline such...
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$279.18 |
Change
2.130(0.77%) |
Mkt cap ! $134.9B | |||
| Open | High | Low | Value | Volume |
| $276.86 | $280.43 | $276.02 | $135.4M | 485.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 81 | $279.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $279.19 | 154 | 1 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$279.74 |
Change
2.130 ( 1.30 %) |
||||
| Open | High | Low | Volume | ||
| $276.75 | $280.38 | $276.31 | 23824 | ||
| Last updated 15.59pm 10/05/2024 ? | |||||
| CSL (ASX) Chart |